CENTESSA PHARMACEUTICALS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.465 USD | +1.38% |
|
-5.29% | +5.53% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 932M |
|---|---|---|---|---|---|
| Net income 2024 * | -182M | Net income 2025 * | -206M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 207M | Net cash position 2025 * | 168M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.39
x | P/E ratio 2025 * |
-5.11
x | Employees | 76 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Centessa Pharmaceuticals plc
More recommendations
More press releases
More news
| 1 day | -4.57% | ||
| 1 week | -6.70% | ||
| Current month | -8.84% | ||
| 1 month | -11.17% | ||
| 3 months | -24.16% | ||
| 6 months | +27.68% | ||
| Current year | +4.90% |
1 week
8.25
9.08
1 month
8.259.97
Current year
6.6512.45
1 year
3.9612.45
3 years
2.8926.90
5 years
2.8926.90
10 years
2.8926.90
| Managers | Title | Age | Since |
|---|---|---|---|
Saurabh Saha
CEO | Chief Executive Officer | 47 | 20-12-31 |
| Director of Finance/CFO | 53 | 21-02-28 | |
Ellie Im
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 21-02-22 | |
| Chairman | 54 | 20-10-31 | |
Brett Zbar
BRD | Director/Board Member | 51 | 20-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 8.4 | +0.60% | 19 903 |
| 24-05-23 | 8.35 | -4.57% | 293,347 |
| 24-05-22 | 8.75 | +1.74% | 212,155 |
| 24-05-21 | 8.6 | -1.38% | 612,133 |
| 24-05-20 | 8.72 | -1.69% | 65,586 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Calendar
2024-06-11
- Goldman Sachs Global Healthcare Conference
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.35
USD
Average target price
13.6
USD
Spread / Average Target
+62.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.90% | 932M | |
| +64.92% | 62.86B | |
| -1.85% | 41.38B | |
| +45.72% | 40.38B | |
| -8.93% | 27.64B | |
| +13.05% | 26.46B | |
| -21.96% | 18.9B | |
| +4.21% | 12.67B | |
| +25.74% | 12.27B | |
| +27.42% | 12.07B |
- Stock Market
- Equities
- CNTA Stock
